TB-500 is the synthetic research analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide found in virtually all nucleated mammalian cells. First isolated from thymic tissue in the 1960s, Thymosin Beta-4 is now understood to be expressed ubiquitously throughout the body — with highest concentrations found in platelets, wound fluid, and actively remodeling tissues, precisely where the body is mounting a repair response.
TB-500’s primary mechanism — actin regulation — places it at the center of cellular migration biology. Cells cannot move without reorganizing their cytoskeleton, and TB-500 directly controls the availability of actin for that reorganization. This makes it one of the most mechanistically fundamental repair peptides in published literature.
Chemical Profile
Full name: Thymosin Beta-4 (synthetic analog) | Amino acids: 43 | Active region: Residues 17-23 (LKKTETQ) | Molecular Weight: ~4,963 Da | Natural source: Expressed in virtually all nucleated mammalian cells; concentrated in platelets and wound fluid
Mechanisms of Action
Actin Regulation — The Core Mechanism
TB-500’s foundational mechanism is the sequestration of G-actin (globular, monomeric actin). Actin is the most abundant protein in eukaryotic cells, existing in dynamic equilibrium between its monomeric form (G-actin) and its polymerized filamentous form (F-actin). This balance governs cell migration, division, and morphological change.
By binding G-actin monomers with high affinity, TB-500 maintains a ready pool of actin available for rapid polymerization when the cell needs to move. This affects lamellipodia and filopodia formation at the cell’s leading edge — the structures that physically drive cell migration through tissue. In wound healing, this enhanced migratory capacity allows fibroblasts, keratinocytes, and endothelial cells to reach injury sites faster and in greater numbers.
Wound Healing Acceleration
Published research demonstrates dramatic wound healing effects. In a full-thickness rat wound model (Malinda et al., 1999, J Invest Dermatol), TB-500 applied topically or intraperitoneally increased re-epithelialization by 42% over controls at 4 days and by up to 61% at 7 days post-wounding. Treated wounds also showed at least 11% more contraction by day 7, along with increased collagen deposition and angiogenesis.
The researchers also found that TB-500 stimulated keratinocyte migration 2-3 fold over controls in Boyden chamber assays at concentrations as low as 10 picograms — an extraordinarily potent effect at remarkably low concentrations.
Anti-Fibrotic Activity
Beyond accelerating healing, TB-500 influences the quality of repair. Published research by Ehrlich and Hazard (2010, Ann N Y Acad Sci) demonstrated that Thymosin Beta-4 organizes connective tissue repair in patterns that reduce scarring by preventing the appearance of myofibroblasts — the cells responsible for fibrotic (scar) tissue formation. This suggests TB-500 may help shift repair outcomes from fibrosis toward regeneration.
Cardiac Repair Research
Some of TB-500’s most significant published research involves cardiac tissue. A landmark 2004 study published in Nature found that Thymosin Beta-4 promoted cardiac cell survival and improved heart function following ischemic injury in mice. The peptide activated dormant epicardial progenitor cells — cardiac stem cells that can generate new heart muscle and vascular tissue. Subsequent research confirmed these cardioprotective effects, with studies showing reduced infarct size and preserved left ventricular function when TB-500 was administered before ischemia-reperfusion injury.
Neurological Research
Published studies in traumatic brain injury models demonstrate neuroprotective effects with TB-500 administration, including improved neurological functional recovery in stroke models. Research identified concentration-dependent effects, with optimal ranges significantly enhancing outcomes compared to controls.
TB-500 in Multi-Peptide Research
TB-500 is most commonly studied alongside BPC-157 — a pairing known as the “Wolverine Stack.” The rationale is mechanistic complementarity: BPC-157 drives angiogenesis (new blood vessel formation via VEGFR2) while TB-500 drives cell migration (via actin regulation). Together they cover two essential and non-overlapping phases of tissue repair.
Adding GHK-Cu extends this further by introducing collagen synthesis and gene expression modulation. Adding KPV provides NF-κB-mediated anti-inflammatory control. PSPeptides offers these combinations as pre-formulated blends:
- GLOW — BPC-157 (10mg) + GHK-Cu (50mg) + TB-500 (10mg) — $79.99
- KLOW — BPC-157 (10mg) + GHK-Cu (50mg) + TB-500 (10mg) + KPV (10mg) — $129.99
Frequently Asked Questions
What is the difference between TB-500 and Thymosin Beta-4?
Thymosin Beta-4 is the full 43-amino acid naturally occurring peptide. TB-500 is the synthetic research peptide corresponding to the active actin-binding region. In research contexts, the terms are often used interchangeably, though TB-500 technically refers to the synthetic form used in laboratory settings.
Why is TB-500 combined with BPC-157?
They target different phases of tissue repair through non-overlapping mechanisms. BPC-157 builds vascular supply (angiogenesis) and modulates nitric oxide signaling. TB-500 enables cell migration (actin regulation) and organizes tissue architecture to reduce scarring. Together they provide broader repair cascade coverage than either alone. See our Wolverine Stack guide for details.
How potent is TB-500?
Remarkably potent at low concentrations. Published research demonstrated significant keratinocyte migration enhancement at concentrations as low as 10 picograms — roughly one trillionth of a gram. This extraordinary potency at minimal concentrations is unusual among repair compounds.
References
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368.
- Ehrlich HP, Hazard SW. Thymosin beta4 enhances repair by organizing connective tissue. Ann N Y Acad Sci. 2010;1194:118-124.
- Smart N, et al. Thymosin beta4 and cardiac repair. Nature. 2004;432:466-472.
- Sosne G, Kleinman HK. Primary mechanisms of Thymosin β4 repair activity in dry eye and other tissue injuries. Invest Ophthalmol Vis Sci. 2015;56(9):5110-5117.
All products are intended for laboratory research use only. Not for human consumption.
PSPeptides — US Made & Shipped | Third-Party Tested | 99%+ Purity | Same-Day Shipping